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generated cluster-disrupted DCs truly
exist in vivo? Second, is DC-specific
disruption of E-cadherin interaction a
physiological mechanism by which
immature DCs develop into DCs that
induce peripheral T cell tolerance to
tissue-specific self-antigens? Disrup-
tion of E-cadherin interactions may
allow DCs to leave peripheral tissues,
and the subsequent upregulation of
CCR7 may direct them to the T cell
areas of secondary lymphoid organs.
The events that induce disruption
under steady-state conditions in vivo,
however, are unclear, especially if one
considers that this event must take
place continuously and on a relatively
large scale to guarantee efficient in-
duction of peripheral tolerance to tis-
sue-specific self antigens, and given
the limited lifetime of a DC. Jiang et al.
(2007) suggest that traumata may be
responsible for disruption of E-cad-
herin interactions of DCs and their sub-
sequent maturation into tolerogenic
APCs. However, most traumata are
accompanied by the production of
inflammatory mediators, which would
result in mature DCs that prime rather
than tolerize. Moreover, it is unclear
whether, in steady state, traumata oc-
cur continuously and ubiquitously. An
exception, as suggested by the au-
thors, may be skin and gut, which are
subjected to movements. An alterna-
tive possibility may be that disruption
of E-cadherin interactions is not ac-
tively induced by an extrinsic event
(e.g., trauma) but that it is intrinsically
programmed to occur at some point
during the DC’s life. Finally, should
the concept that resting immature DC
induce peripheral tolerance (Probst
et al., 2005; Steinman et al., 2003)
be modified, or do both mechanisms
of tolerance induction exist next to
each other? Investigation into whether
molecules suchas the inhibitory recep-
tor PD-1, transforming growth factor-
b, and indoleamine-2,3-dioxygenase
(Mellor and Munn, 2004; Probst et al.,
2005) also play a role in tolerance
mediated by CD-matured DCs may
clarify this issue, because involvement
of similar surface and intracellular mol-
ecules in both pathways at least sug-
gests that they are related, if not the
same.
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Interleukin-17 (IL-17)-producing helper T cells play a role in pathogen defense and autoimmunity. In
this issue of Immunity, van Beelen et al. (2007) reveal a pathway that elicits potent IL-17 production
from memory T cells through activation of the intracellular receptor NOD2.In 1986, Mosmann and Coffman intro-
duced the Th1-Th2 paradigm by dem-
onstrating that helper T (Th) cells could
be separated into stable subsets that
produced distinct patterns of effector
cytokines (Mosmann et al., 1986).
Over the years since this discovery, it
has become clear that Th cells, under
the guidance of innate immune path-
ways, differentiate to tailor the adap-546 Immunity 27, October 2007 ª2007 Etive immune response to the nature
of the microbial threat. In general,
Th1 cells are important for protection
against viruses and intracellular bac-
teria, whereas Th2 cells coordinate im-
munity to extracellular parasites atmu-
cosal surfaces. One of the enduring
features of the Th1-Th2 model is its
predictive power: The properties of
an effector Th cell reflect a specific mi-lsevier Inc.crobial stimulus, interpreted by an an-
tigen-presenting cell and relayed to
the naive T cell in the form of MHC-
peptide complexes, inducible costi-
mulation, and instructive cytokines.
As we have learned more about the
innate immune pathways that detect
infection and characterized more of
the 75 cytokines in the mammalian
genome, the possibilities for other
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Previewseffector Th cell subsets have ex-
panded, but the basic rules remain
the same.
Recently, another Th cell subset was
discovered and named Th17 for its
ability to produce interleukin 17 (IL-
17) (reviewed in Weaver et al. [2007]).
Many immunologists have now turned
their attention to understanding the
differentiation and function of Th17
cells, by applying the logic and tech-
niques developed over two decades
of dissecting the Th1-Th2 paradigm.
Figure 1. NOD2 Activates Th17 Effector
Function in Human Memory CD4+ T Cells
The pathway defined by van Beelen et al.
(2007) reveals that NOD2 activation byMDP re-
sults in potent production of IL-1 and IL-23,
which prime memory CD4+ T cells to produce
IL-17. Important issues that remain to be ex-
plored include a mechanistic connection be-
tween NOD2 and caspase-1, possibly through
the CARDs of these two proteins, and the sig-
naling pathway that links NOD2 activation to
transcription of IL-23 p19. It will also be inter-
esting to determine whether NOD2 stimulation
also activates a regulatory pathway to limit
Th17 effector function.A number of key elements of the
Th17 program have been defined:
specific microbial stimuli detected by
the innate immune cells that initiate
Th17 differentiation (bacteria and fungi),
a ‘‘master regulator’’ transcription fac-
tor that drives the Th17 gene-expres-
sion program (ROR-gT), and important
effector functions of Th17 cells, which
include neutrophil recruitment to
sites of inflammation (Stockinger and
Veldhoen, 2007). The proinflammatory
nature of Th17 cells is protective
against certain bacterial infections but
has also been linked to a number of au-
toimmune diseases, thus establishing
the Th17axis as an important therapeu-
tic target.
One key question that has received
much attention is the nature and origin
of the cytokines that instruct and en-
force Th17 cell fate. In the mouse sys-
tem, IL-6 and transforming growth fac-
tor b (TGF-b) synergize to initiate Th17
differentiation in naive T cells, whereas
IL-23 is required for sustaining effector
Th17 cells in both protective and auto-
immune settings (reviewed in Stock-
inger and Veldhoen [2007]). Whether
these cytokines are activated by the
same innate pathways and which in-
nate receptors initiate their production
remained unknown.
Kapsenberg, de Jong, and their col-
leagues explored the innate stimuli re-
quired to prime human T cells to pro-
duce IL-17 (van Beelen et al., 2007
[this issue of Immunity]). They first
demonstrated that monocyte-derived
dendritic cells (DCs) exposed to bac-
teria, but not viruses, elicit strong IL-17
responses in cultured human T cells.
Of several known innate immune stim-
uli, bacterial peptidoglycan (PGN) was
most potent at eliciting IL-17 produc-
tion. When the authors examined puri-
fied, naive human T cells, they were
surprised to find that the optimal con-
ditions for Th17 differentiation defined
in the mouse (TGF-b and IL-6) were
insufficient to instruct naive human
T cells to become Th17 cells and that
the IL-17 produced in the PGN-stimu-
lated coculture was confined to mem-
ory T cells. In fact, none of the in vitro
conditions tested on monocyte-
derived DCs, including PGN, were
able to drive naive human T cells along
the Th17 pathway. A recent paper re-Immunity 2ported the same finding and shed fur-
ther light on the initiation of human
Th17 differentiation (Acosta-Rodriguez
et al., 2007). Sallusto and colleagues
showed that freshly isolated human
monocytes and DCs, but not DCs cul-
tured from human blood like the ones
used by van Beelen et al. (2007), could
initiate Th17 differentiation in naive T
cells and that IL-1b and IL-6, but not
TGF-b, were the relevant instructive
cytokines. When considered together,
the data reported by these groups
show that the cytokine requirements
for initial commitment to the Th17 line-
age differ between human and mouse
and that the cell types that can initiate
differentiation and activate effector
function of human Th17 cells in vitro
might be different.
van Beelen et al. (2007) found that
PGN-activated DCs selectively pro-
duce IL-1a and IL-1b and the p19 sub-
unit of IL-23, a cytokine implicated
in maintenance of effector Th17 cells.
By using blocking antibodies, the
authors demonstrated that IL-1 and
IL-23 were necessary for inducing
memory T cells to make IL-17. Inter-
estingly, muramyl dipeptide (MDP),
a product of PGN catabolism and a
ligand for NOD2 (nucleotide-binding
oligomerization domain containing 2),
was responsible for stimulating pro-
duction of these cytokines. NOD2 is
a member of a family of intracellular in-
nate immune receptors and is often
mutated in Crohn’s disease (CD), an
autoimmune condition characterized
by excessive intestinal inflammation
(Meylan et al., 2006). Remarkably, mis-
regulation of IL-23 and the Th17 axis
have been implicated in the pathogen-
esis of CD (Duerr et al., 2006). Two
complementary experiments further
established the role of MDP and
NOD2 in activating Th17 effector func-
tion in this system. First, MDP con-
ferred potent IL-1 and IL-23 stimulatory
activity when used in combination with
TLR ligands to activate DCs. Second,
NOD2 mutant DCs derived from
patients with Crohn’s disease failed to
efficiently activate effector Th17 cells
when stimulated with PGN or a combi-
nation of MDP and Toll-like receptor
(TLR) ligands.Thesedatadefineapath-
way for IL-1- and IL-23-dependent
priming of effector Th17 cells through7, October 2007 ª2007 Elsevier Inc. 547
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lular MDP, thus connecting two sys-
tems implicated in the pathogenesis
of Crohn’s disease (Figure 1).
IL-1b production is regulated by an
unusual two-step process, in which
transcription and translation of the pro-
cytokine is uncoupled from process-
ing and secretion of its biologically
active form. TLR ligands are the most
potent stimulators of pro-IL-1b syn-
thesis but do not direct its processing,
whereas activators of the caspase-1
inflammasome stimulate processing
and secretion of preformed pro-IL-1b
(Meylan et al., 2006). The finding that
activation of NOD2 by MDP is required
for optimal production of IL-1b by
human DCs implies a functional interac-
tion between NOD2 and the caspase-1
inflammasome. Evidence supporting
such a role for NOD2 in activating
IL-1b processing has been reported
(Maeda et al., 2005), but mechanis-
tic data linking NOD2 to caspase-1
remain elusive. Because IL-23 p19
expression is coregulated with IL-1b
secretion through NOD2-dependent
signaling, it would also be of interest
to determinewhether caspase-1 is also
involved in production of IL-23.
The authors usedNOD2mutant DCs
from Crohn’s patients to show that
NOD2 mediates the PGN-activated
IL-1 and IL-23 response that primes
optimal IL-17 production by memory
Th cells. Taken at face value, this find-
ing suggests a deficit in Th17 effector
function in Crohn’s patients and thus
implies that Th17 cells are protec-
tive—rather than pathogenic—in the
context of inflammatory bowel disease
(IBD). However, accumulating evi-
dence in both mice and humans sug-
gests that Th17 cells are a principal
cause of autoimmune pathology in di-
verse settings, including IBD, experi-
mental autoimmune encephalomyeli-
tis, and arthritis (reviewed in Weaver548 Immunity 27, October 2007 ª2007 Eet al. [2007]). Moreover, the in vitro as-
says used by van Beelen et al. (2007)
suggest that the NOD2 mutations re-
sult in a loss of function; whether these
mutations predispose to CD in vivo
through a loss or a gain of function is
a hotly debated topic with data that
support either interpretation (Eckmann
andKarin, 2005). Indeed, knockinmice
with mutant NOD2 alleles homologous
to the 3020Cinsmutation in the human
DCs used by van Beelen et al. (2007)
demonstrated increased activation of
the transcription factor NF-kB and ele-
vated secretion of IL-1b (Maeda et al.,
2005). The authors also mention that
CD lesions fromNOD2mutant patients
contained similar numbers of Th17
cells when compared with lesions
from CD patients with wild-type NOD2.
NOD2 therefore appears tobedispens-
able for activating Th17 effector func-
tion in the complex environment of an
inflamed intestine.
Despite the complexities of the
in vivo role of NOD2 in CD, NOD2
stimulation can clearly elicit robust
Th17 effector function in vitro; indeed,
NOD2 is far more potent than TLRs in
coaxing human memory Th cells to
make IL-17. One possible explanation
of this apparent dichotomy invokes
a common theme in innate immunity
wherein receptors that detect micro-
bial stimuli activate both a proinflam-
matory response tailored to the
stimulus and a specific regulatory
pathway to limit the duration and
scope of that inflammation. It appears
that multiple pathways, including
NOD2, can redundantly engage the
Th17 axis. However, if NOD2 can ac-
tivate Th17 cells as shown by van
Beelen et al. (2007), it should also be
able to limit their function. Perhaps it
is this regulatory role that is nonre-
dundant in the intestine. In NOD2 mu-
tant CD patients, Th17 cells activated
by other pathways would cause in-lsevier Inc.testinal pathology because NOD2-
dependent immunoregulatory mecha-
nisms specific for Th17 cells are
absent. Although this model is specu-
lative, sequential proinflammatory and
anti-inflammatory responses are acti-
vated downstream of every known in-
nate immune pathway, and a negative
regulatory role for NOD2 in the innate
immune response to PGN has re-
cently been proposed (Watanabe
et al., 2006). The link between NOD2
and Th17 effector function warrants
further exploration of this theme,
with interesting implications for the
pathology of inflammatory bowel dis-
ease.
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